Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Short Interest Down 23.0% in January

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 70,538 shares, a decrease of 23.0% from the December 31st total of 91,573 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. Currently, 0.4% of the company’s stock are sold short.

Newron Pharmaceuticals Price Performance

Shares of NWPHF opened at $9.36 on Friday. The company’s 50 day moving average price is $9.36 and its 200 day moving average price is $9.36. Newron Pharmaceuticals has a 52 week low of $9.10 and a 52 week high of $12.00.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.